Agent
PCSK9 inhibitors (evolocumab, alirocumab, inclisiran)
Status Approved for LDL-C; lower Lp(a) by 20 to 30 percent as a secondary effect
Monoclonal antibodies lower Lp(a) by a median 25 to 30 percent (inclisiran about 22 percent) and the trial analyses suggest part of their benefit runs through Lp(a): larger absolute risk reductions at high baseline Lp(a) in FOURIER (Circulation 2019) and VESALIUS-CV (Circulation 2026), and alirocumab-induced Lp(a) lowering independently predicting fewer events in ODYSSEY OUTCOMES (JACC 2020, EHJ 2020). Not an Lp(a) therapy, but the strongest tool available today for the high-Lp(a) patient with residual LDL-C.
Page updated 17 August 2026.